Diabetes Medication Selection in CKD

Obtain eGFR and urine albumin-to-creatinine ratio (UACR) before choosing a glucose-lowering regimen. In type 2 diabetes, CKD defined by eGFR below 60 mL/min/1.73 m2 or UACR of at least 30 mg/g identifies patients with a guideline-level indication for SGLT2 inhibitor therapy; missing albuminuria data can obscure eligibility in patients without known heart failure or ASCVD. jaccjaccPrescription Patterns for Sodium-Glucose Cotransporter 2 Inhibitors in U.S. Health Systems

For adults with type 2 diabetes and confirmed eGFR 20-60 mL/min/1.73 m2 and/or albuminuria, select an SGLT2 inhibitor or GLP-1 receptor agonist with demonstrated benefit irrespective of A1C or concurrent metformin. The choice should be driven by the dominant preventable outcome: SGLT2 inhibitors for CKD progression and heart failure risk, and GLP-1 receptor agonists when cardiovascular risk reduction, glucose lowering, or avoidance of hypoglycemia at advanced CKD predominates. Diabetes Journals+1Diabetes Journals9. Pharmacologic Approaches to Glycemic Treatment: Standards of ...Diabetes Journals11. Chronic Kidney Disease and Risk Management: Standards of ...

Do not use the diminished glucose-lowering effect of SGLT2 inhibition at eGFR below 45 mL/min/1.73 m2 as a reason to withhold kidney- and heart-failure-directed treatment. At this threshold, reassess glycemic therapy separately and add or prioritize a GLP-1 receptor agonist when further A1C lowering is needed. Diabetes Journals+1Diabetes Journals9. Pharmacologic Approaches to Glycemic Treatment: Standards of ...nice org ukInitial medicines | Type 2 diabetes in adults: management | Guidance | NICE

For most adults with type 2 diabetes and CKD, initiate an SGLT2 inhibitor once eGFR is at least 20 mL/min/1.73 m2, including patients who already meet their individualized glycemic target on other agents. Current ADA guidance recommends this approach to reduce CKD progression and cardiovascular events, with heart failure risk reduction independent of glucose management. Diabetes Journals+1Diabetes Journals11. Chronic Kidney Disease and Risk Management: Standards of ...Diabetes Journals9. Pharmacologic Approaches to Glycemic Treatment: Standards of ...

If the patient has CKD plus established ASCVD, heart failure, or high ASCVD risk, an SGLT2 inhibitor and/or GLP-1 receptor agonist with demonstrated cardiovascular benefit is recommended regardless of A1C and whether metformin is being used. For a patient with a competing heart-failure or progressive-CKD priority, choose the SGLT2 inhibitor first; comparative observational evidence found lower 5-year CKD risk and fewer acute kidney injury events with SGLT2 inhibitor initiation than with GLP-1 receptor agonist initiation. Diabetes Journals+1Diabetes Journals9. Pharmacologic Approaches to Glycemic Treatment: Standards of ...JAMASGLT2 Inhibitors vs GLP-1 Receptor Agonists for Kidney Outcomes in Individuals With Type 2 Diabetes

Expect a reversible early eGFR decline after SGLT2 inhibitor initiation. This hemodynamic change generally does not require discontinuation; SGLT2 inhibitor use appears protective against acute kidney injury. Continue treatment below the initiation eGFR threshold unless intolerance or another clinical reason requires cessation. PubMedPubMedDiabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)

Before initiation, review volume status and diuretic use. In patients at high risk for hypovolemia, consider a proactive diuretic dose reduction and monitor for volume depletion. Hold the SGLT2 inhibitor during acute illness; use a sick-day protocol and maintain at least low-dose insulin in insulin-requiring patients to reduce diabetic ketoacidosis risk. PubMedPubMedDiabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)

Use a GLP-1 receptor agonist with demonstrated cardiovascular benefit in type 2 diabetes and CKD when cardiovascular event reduction is a predominant objective, when additional glycemic lowering is required after kidney-directed therapy, or when SGLT2 inhibitors cannot be used. ADA guidance recommends a GLP-1 receptor agonist for reduction of cardiovascular risk and CKD progression in this population. Diabetes Journals+1Diabetes Journals11. Chronic Kidney Disease and Risk Management: Standards of ...Diabetes Journals9. Pharmacologic Approaches to Glycemic Treatment: Standards of ...

At eGFR below 30 mL/min/1.73 m2, a GLP-1 receptor agonist is preferred for glycemic management because of lower hypoglycemia risk. This is the key branch in advanced CKD: retain an SGLT2 inhibitor previously started for cardiorenal benefit when clinically appropriate, but do not rely on it for glucose lowering. Diabetes Journals+1Diabetes Journals9. Pharmacologic Approaches to Glycemic Treatment: Standards of ...PubMedDiabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)

Semaglutide has kidney-outcome trial evidence in type 2 diabetes with CKD: the FLOW trial randomized patients to semaglutide 1 mg subcutaneously weekly or placebo, including participants with eGFR 25-75 mL/min/1.73 m2 and substantial albuminuria. Baseline SGLT2 inhibitor use was permitted, supporting combined use when each class has an independent clinical indication. NatureNatureEffects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial | Nature Medicine

Mitigate gastrointestinal intolerance by starting the GLP-1 receptor agonist at its lowest recommended dose and titrating slowly. Counsel specifically about nausea, vomiting, and diarrhea; these symptoms can compromise volume status in CKD and should trigger reassessment of oral intake and concurrent diuretic exposure. PubMedPubMedDiabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)

Continue or initiate metformin only when eGFR is at least 30 mL/min/1.73 m2. Reduce the total daily dose to 1,000 mg at eGFR 30-44 mL/min/1.73 m2; also consider reducing to 1,000 mg daily at eGFR 45-59 mL/min/1.73 m2 in patients at high risk of lactic acidosis. FDA guidance cited in cardiovascular pharmacology literature lists metformin as contraindicated below eGFR 30 mL/min/1.73 m2 and does not recommend initiation at eGFR 30-45 mL/min/1.73 m2. PubMed+1PubMedDiabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)jaccDiabetic Agents, From Metformin to SGLT2 Inhibitors and GLP1 ...

When eGFR is below 30 mL/min/1.73 m2 and a GLP-1 receptor agonist is unsuitable or insufficient, a DPP-4 inhibitor is an alternative glucose-lowering option in renal impairment. Linagliptin has the practical advantage of not requiring dose adjustment as renal function declines; this is useful when injection therapy is not feasible and hypoglycemia avoidance is important. cdn clinicaltrialscdn clinicaltrials[PDF] Protocol for non-interventional studies based on ... - ClinicalTrials.gov

For any transition to SGLT2 inhibitor or GLP-1 receptor agonist therapy, proactively reduce hypoglycemia exposure from insulin or sulfonylureas when clinically indicated. ADA emphasizes that the preferred cardiorenal agents can be added or substituted despite A1C at target, so background regimens should be redesigned rather than simply layered without reassessment. PubMed+1PubMedDiabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)Diabetes Journals9. Pharmacologic Approaches to Glycemic Treatment: Standards of ...

For type 2 diabetes with CKD and albuminuria, use a nonsteroidal mineralocorticoid receptor antagonist shown effective in clinical trials when eGFR is at least 25 mL/min/1.73 m2. ADA recommends finerenone-class therapy to reduce cardiovascular events and CKD progression in albuminuric CKD, with potassium monitoring as an explicit requirement. Diabetes JournalsDiabetes Journals11. Chronic Kidney Disease and Risk Management: Standards of ...

The FIDELIO-DKD and FIGARO-DKD pooled program enrolled patients receiving optimized renin-angiotensin system blockade with either UACR 30 to less than 300 mg/g and eGFR 25-90 mL/min/1.73 m2, or UACR 300-5,000 mg/g and eGFR at least 25 mL/min/1.73 m2. Use this phenotype to identify the patient most closely aligned with the outcome-trial population. Wolters KluwerWolters KluwerFinerenone in Patients with CKD and Type 2... : Journal of the American Society of Nephrology

Do not treat finerenone as a substitute for an SGLT2 inhibitor or GLP-1 receptor agonist when those agents are indicated. In FIDELITY, finerenone reduced the cardiovascular composite endpoint irrespective of baseline SGLT2 inhibitor use; combination therapy in albuminuric G1-G3 CKD produced greater 6-month UACR reduction than either treatment alone without excess safety risk in the cited combination trial. Wolters Kluwer+1Wolters KluwerFinerenone in Patients with CKD and Type 2... : Journal of the American Society of NephrologyWolters KluwerASN Kidney Health Guidance on the... : Journal of the American Society of Nephrology

Monitor potassium after finerenone initiation and during therapy. Hyperkalemia is the principal monitoring tradeoff; SGLT2 inhibitor and diuretic use may mitigate hyperkalemia risk with mineralocorticoid receptor antagonists and renin-angiotensin system inhibitors, but potassium surveillance remains required. Diabetes Journals+1Diabetes Journals11. Chronic Kidney Disease and Risk Management: Standards of ...Wolters KluwerASN Kidney Health Guidance on the... : Journal of the American Society of Nephrology